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INTRODUCTION: The extensive use of prostate-specific
antigen as a general prostate cancer biomarker has in-
troduced the hazards of overdiagnosis and overtreat-
ment. Recent studies have revealed the immense bio-
marker capacity of microRNAs (miRNAs) in prostate
cancer. The aim of this study was to analyze the expres-
sion pattern of miR-224, a cancer-related miRNA, in
prostate tumors and investigate its clinical utility.
METHODS: Total RNA was isolated from 139 prostate
tissue samples. After the polyadenylation of total RNA
by poly(A) polymerase, cDNA was synthesized with a
suitable poly(T) adapter. miR-224 expression was
assessed by quantitative real-time PCR and analyzed
with the comparative quantification cycle method,
Cq(2
Cq).We performed comprehensive biostatisti-
cal analyses to explore the clinical value of miR-224 in
prostate cancer.
RESULTS: miR-224 expression was significantly down-
regulated in malignant samples compared with benign
samples (P 0.001). HighermiR-224 expression levels
were found in prostate tumors that were less aggressive
(P 0.017) and in an earlier disease stage (P 0.018).
Patients with prostate cancer who were positive for
miR-224 had significantly enhanced progression-free
survival intervals compared with miR-224–negative
patients (P 0.021). Univariate bootstrap Cox regres-
sion confirmed that miR-224 was associated with
favorable prognosis (hazard ratio 0.314, P  0.013);
nonetheless, multivariate analysis, adjusted for con-
ventional markers, did not identify miR-224 as an in-
dependent prognostic indicator.
CONCLUSIONS: miR-224 is aberrantly expressed in pros-
tate cancer. Its assessment by cost-effective quantita-
tive molecular methodologies could provide a useful
biomarker for prostate cancer.
© 2012 American Association for Clinical Chemistry
Prostate-specific antigen (PSA)3 is one of the most ex-
tensively used cancer biomarkers (1 ). Nevertheless, the
importance of PSA in prostate cancer (CaP) screening
and prognosis is still being challenged (1, 2 ), since any
benefits of PSA testing come with the costs of over-
diagnosis and overtreatment. Apart from the un-
doubted physiological and psychological inconve-
nience for the patients, the increased financial costs for
healthcare systems globally should be taken into ac-
count as well, considering also the high prevalence of
prostate malignancies (1, 2 ). Consequently, there is an
urgent need for novel CaP biomarkers.
Numerous studies illustrate that microRNAs
(miRNAs) are aberrantly expressed in human malig-
nancies, including CaP (3–5). Because miRNAs exert
key roles in carcinogenesis and tumor progression,
miRNA genes (MIR)4 are currently considered a novel
class of oncogenes or tumor suppressor genes (6 ).
Moreover, miRNAs are regarded as promising bio-
markers and therapeutic tools for human neoplasms,
including urologic tumors (3 ). Recent studies describe
the important diagnostic, prognostic, and predictive
role of miRNAs in CaP (3, 4 ). Nonetheless, the major-
ity of these studies are based on microarray expression
data that are characterized by inconsistencies, since no
significant overlap has been reported between them
(5, 7 ).
The aim of this study was to comprehensively pro-
file the expression of the mature miRNA 224 (miR-
224) molecule in benign prostatic hyperplasia (BPH)
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and CaP with a reliable and cost-efficient method
based on quantitative real-time PCR (qPCR).We chose
tissue samples frompatients with BPH as a control group
to provide an initial assessment ofmiR-224 as a potential
discriminator of malignant from common benign tu-
mors.Wealso investigated theprognosticperformanceof
miR-224 inCaPwith respect to prediction of disease pro-
gression. We selected miR-224 for analysis because of its
repeatedly reported aberrant expression in various hu-
man malignancies (8–22) and its capacity for targeting
numerous cancer-related genes.
Materials andMethods
PROSTATE TISSUE SAMPLES
This study was carried out according to the ethical
principles of the 1975 Declaration of Helsinki, as re-
vised in 2008. Approval for the use of the prostate tissue
samples was acquired by the ethical committee of
“Laiko” University Hospital. Informed consent was
provided by all participating patients.
We analyzed 139 snap-frozen tumor tissue sam-
ples from patients with BPH (n 66) or CaP (n 73)
(see Supplemental Table 1, which accompanies the on-
line version of this article at http://www.clinchem.org/
content/vol59/issue1), collected at the “Laiko” Univer-
sity Hospital, Athens, Greece. Patients with BPH had
undergone surgery with either a transurethral or open
prostatectomymethod, whereas radical prostatectomy
was performed in patients with CaP. No hormonal
treatment or radiotherapy was given to the patients of
this study before surgery. A tissue sample of approxi-
mately 200 mg was sectioned from the peripheral zone
of the prostate gland of patients with CaP on the basis
of the preoperative features of the biopsy and macro-
scopic findings. Subsequently, with the purpose of cor-
roborating the presence of malignancy, two mirror-
image segments were produced and one part of each
sample was assessed by the same pathologist. The re-
maining part was snap-frozen in liquid nitrogen and
stored at80 °Cuntil analysis. Only the tissueparts that
were confirmed as malignant from CaP, as well as the
tissue samples obtained from the adenomectomy of pa-
tients with BPH, were used for subsequent analysis. Fif-
teen patients were excluded from the survival analysis be-
cause of (a) unavailability at follow-up; (b) unavailability
of precise monitoring information; or (c) administration
of adjuvant therapy, after radical prostatectomy and be-
fore any biochemical relapse, to high-risk patients (e.g.,
individuals with positive surgical margins).
PSA MEASUREMENTS
For preoperative and postoperative PSA measure-
ments, 5 mL venous blood was sampled and left to clot
at room temperature for 1 h. After centrifugation of the
blood samples at 2000g for 15min, serum samples were
collected and stored at70 °C until measurement.We
measured PSA serum concentrations with the com-
mercially available PSA-RIACT™ immunoradio-
metric assay kit (Cis Bio International), according to
the manufacturer’s instructions. Intraassay and in-
terassay CVs of the above method were 2.4% and
3.9%, respectively. Serum PSA concentrations after
radical prostatectomy for all patients included in the
survival analysis were 0.1 g/L. The time to bio-
chemical relapse was defined as the period between
surgery and the persistent increase of serum PSA
concentrations, evidenced by 2 consecutive PSA re-
sults 0.2 g/L.
RNA EXTRACTION
We extracted total RNA from prostate tissue samples,
after pulverization and homogenization, as well as
from the LNCaP cells, with the TRI reagent® (Molecu-
lar Research Center), according to the manufacturer’s
instructions. The resulting RNA pellet was dissolved in
RNA Storage Solution (Applied Biosystems/Ambion)
and stored in aliquots at 80 °C until use. We deter-
mined total RNA concentration and purity spectro-
photometrically and confirmed RNA integrity by aga-
rose gel electrophoresis.
POLYADENYLATION AND cDNA SYNTHESIS
Isolated total RNA (1 g), including miRNAs, was
polyadenylated in the presence of ATP (80 mol/L) by
1 U poly(A) polymerase (New England Biolabs) at
37 °C for 1 h. The reaction buffer consisted of 50
mmol/L Tris-HCl, 250 mmol/L NaCl, and 10 mmol/L
MgCl2. The enzyme was heat-inactivated at 65 °C for
10 min.
The resulting polyadenylated RNA was then
mixed with poly(T) adapter, 5-GCGAGCACAGAAT
TAATACGACTCACTATAGGTTTTTTTTTTTTVN-3
(0.25 mol/L) where V G, A, C and N G, A, T, C,
heated at 70 °C for 5 min, and quick-cooled on ice to
denature any secondary structures and allow the an-
nealing of the poly(T) adapter. We performed re-
verse transcription into cDNA by adding 100 U
Moloney murine leukemia virus reverse transcrip-
tase (Invitrogen), 40 U recombinant ribonuclease
inhibitor (Invitrogen), and the reaction buffer (50
mmol/L Tris-HCl, 75 mmol/L KCl, 3 mmol/L
MgCl2, 10 mmol/L dithiothreitol, and 0.5 mmol/L of
each dNTP). The final reaction volume was 20 L.
We terminated reverse transcription (37 °C for 60
min) by incubation at 70 °C for 15 min.
qPCR
On the basis of published sequences of mature miR-
224 and SNORD48 (small nucleolar RNA, C/D box 48)
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(GenBank accession numbers NR_029638 and
NR_002745, respectively), we designed 2 specific for-
ward primers. The sequences of the miR-224–specific
primer was 5-CAAGTCACTAGTGGTTCCGTTAA-
3, and that of the SNORD48-specific primers was 5-
TGATGATGACCCCAGGTAACTCT-3. We used a
sequence hybridizing to the poly(T) adapter (5-
GCGAGCACAGAATTAATACGAC-3) as the reverse
primer. The resulting PCR amplicons during miR-224
and SNORD48 amplification were 65 and 105 bp long,
respectively. We selected SNORD48 (RNU48) for nor-
malization purposes owing to its broad use as a refer-
ence molecule for miRNA expression studies in CaP
and its reported biological stability (23–26). We also
found that SNORD48 expression was not significantly
different between tissue samples from patients with
BPH and patients with CaP or between samples from
patients with various disease stages or Gleason scores.
Quantitative real-time PCR was carried out with the
SYBR® green chemistry, in 96-well PCR microplates
(Axygen) placed in a 7500 Real-Time PCR System (Ap-
plied Biosystems). We assessed the fluorescence emis-
sion of the products and subsequent calculations by use
of Sequence Detection System software (Applied Bio-
systems). The reaction mixture (10 L total volume per
well) included 2 ng cDNA, 2.5L diethylpyrocarbonate-
treatedwater (AppliedBiosystems), 5LKapaSYBRFast
Universal 2X qPCRMaster Mix (Kapa Biosystems), 0.2
L of 50 Rox Low passive reference dye (Kapa Bio-
systems), and primers at a final concentration of 200
nmol/L. The reactionswere performed in duplicate un-
der the following conditions: 95 °C for 3 min as an
initial step followed by 40 cycles of 95 °C for 15 s and
59 °C for 60 s. After amplification, we produced disso-
ciation curves (59 °C to 95 °C at a heating rate of
0.1 °C/sec and acquiring fluorescence data every
0.3 °C) to discriminate the main reaction products
from other nonspecific ones or primer-dimers. Fur-
thermore, we subjected randomly selected miR-224
and SNORD48 PCRproducts to electrophoresis on 3%
wt/vol agarose gels to corroborate the presence of a
unique amplicon. Each qPCR run always included a
no-cDNA template control. Additionally, reverse tran-
scription negative controls were tested and the use of
DNA as a qPCR template was analyzed. All the afore-
mentioned negative controls gave no detectable quan-
tification cycle (Cq) value, corroborating the lack of any
contamination or nonspecific signal.
We computed the results by the comparative
Cq(2
Cq) method. The normalized results of the ex-
pression analysis are presented as relative quantifica-
tion (RQ) units (2Cq) demonstrating the expres-
sion ratio of miR-224/SNORD48. Cq is equal to the
difference between the Cq of the target molecule (miR-
224) and the threshold cycle of the corresponding en-
dogenous reference (SNORD48) in each sample.Cq
is the difference between theCq values of a test sample
and the calibrator sample (LNCaP cells).We conducted
a validation experiment to test the requirements for ap-
plying theabovemethodology.Adilutionseriesof control
cDNA, incorporating several orders of magnitude, was
amplified, andCq valueswereplotted against log10[cDNA
quantity]. We estimated reaction efficiency (E) with the
formula,E% [1 10(1/slope)] 100.We also deter-
mined the intraassay and interassay CVs of the RQ units
for this qPCR assay.
STATISTICAL ANALYSES
We used nonparametric Mann–Whitney U and the
Kruskal–Wallis statistical tests to analyze the differ-
ences of miR-224 expression values between patient
groups. Prediction of the presence of CaP was per-
formed by use of univariate and multivariate binary
logistic regressionmodels.We determined associations
between the continuous variables of the study by use of
Spearman correlation coefficient (rs). Survival analyses
were performed with Kaplan–Meier curves, dichoto-
mizedmiR-224 status according to the median expres-
sion in CaP (2.145 RQ units), and the log-rank statis-
tical test for comparison, as well as bootstrap Cox
proportional hazards regression models. An ROC
curve was generated under the nonparametric distri-
bution assumption for miR-224 expression levels by
plotting sensitivity vs (1  specificity). The outcome
determined was the presence of CaP (test direction:
smaller test result indicates more positive test). The
calculations for the area under the curve (AUC) were
based on the method of Hanley and McNeil (27). We
performed statistical analyses with IBM SPSS® soft-
ware, version 20.0.0; P values 0.05 were considered
statistically significant.
Results
QUANTITATIVE ASSESSMENT OF miR-224 EXPRESSION LEVELS
IN PROSTATE TUMORS
Confirmation of specific amplification of the preferred
amplicons is presented in online Supplemental Fig. 1,
evidenced by a unique peak at the melting curve anal-
ysis (miR-224 product Tm 73.3 °C, SNORD48 prod-
uct Tm 79.6 °C) and the detection of a single distinc-
tive band by agarose gel electrophoresis for randomly
selected prostate tissue samples. The efficiencies of
miR-224 and SNORD48 amplification, calculated
from the slopes (3.562, r2  0.9996, and 3.482,
r2  0.9955, respectively) of the curves deriving from
the validation experiments, were 91% and 94%. This
proves that the PCR amplicons were produced with
similar efficiencies and consequently allowed the use of
theCq calculationmethod. The intraassay CVof the
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expression units (RQ) was 2.92%, whereas the interas-
say CV ranged from 6.29% to 9.13%.
DOWNREGULATION OF miR-224 EXPRESSION IN BPH COMPARED
TO CaP SAMPLES
The expression of miR-224 was significantly decreased
(P 0.001) in CaP compared with BPH samples (Fig.
1A; Table 1). ThemedianmiR-224 expression level was
2.145 RQ units in the malignant and 3.706 RQ units in
the benign prostate tissue samples (Fig. 1A; Table 1).
We used ROC curve analysis to evaluate the discrimi-
natory potential of this miRNA for patients with BPH
and CaP. miR-224 could distinguish patients with CaP
from patients with BPH with an AUC of 0.672 (95% CI
0.583–0.761, P  0.001) (Fig. 1B). The corresponding
AUCforPSAwas0.785(95%CI0.695–0.875,P0.001).
We further corroborated the discriminatory value
ofmiR-224 by both univariate andmultivariate logistic
regression analyses (Table 2). Men who presented with
increased levels of miR-224 expression became less
likely (crude odds ratio 0.534, 95% CI 0.322–0.884) to
have CaP (P  0.015). Corresponding multivariate
models, also corrected for serum PSA concentrations
and digital rectal exam status, which are the most im-
portant indicators of prostate malignancy, revealed the
independent discriminatory capacity of miR-224 ex-
pression (crude odds ratio 0.381, 95%CI 0.168–0.864,
P 0.021) (Table 2).
Fig. 1. (A), Downregulation of miR-224 in patients with CaP compared to patients with BPH.
Bold lines represent the median value. *Outliers. (B), ROC curve analysis for miR-224 expression levels.
Table 1. Distribution of miR-224 expression levels, serum PSA concentrations, and age in patients with CaP or BPH.
Variable Mean  SE Range
Percentile
10th 25th
50th
(median) 75th 90th
Patients with CaP (n  73)
miR-224 expression, RQa 4.228 0.809 0.086–46.64 0.3632 0.7070 2.145 4.327 10.32
PSA, ng/mL 9.23 0.69 2.20–41.8 4.17 5.54 7.65 11.6 15.6
Age, years 64.8 0.74 52–76 56 60 64 70 74
Patients with BPH (n  66)
miR-224 expression, RQa 8.470 2.09 0.4090–118.7 1.127 1.994 3.706 9.139 15.21
PSA, ng/mL 5.11 0.72 0.400–25.6 1.10 1.59 3.89 6.14 12.2
Age, years 69.6 0.95 49–86 60 65 70 75 80
a Normalized to SNORD48 expression.
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miR-224 EXPRESSION IN RELATION TO CLINICOPATHOLOGICAL
VARIABLES
miR-224 expression gradually decreased in patients
with more aggressive tumors (P  0.017) (Fig. 2A).
Median miR-224 expression in the group of patients
with Gleason score 6 was 2.63 RQ units, and it de-
creased progressively in Gleason score 7 (median 1.84
RQ units) and Gleason score 	7 (median 0.725 RQ
units) prostate tumors. Additionally, patients with ad-
vanced disease, indicated by pathological stagepT2c,
where the tumor has progressed to both prostatic lobes
or even further, showed significantly (P 0.018) lower
miR-224 expression (median 1.27 RQunits) compared
with pathological stage pT2c patients (median 2.63
RQ units), where the malignancy is confined in one
prostatic lobe (Fig. 2B). The negative correlation be-
tween miR-224 expression and both greater Gleason
score and advanced disease stage was also confirmed by
Spearman analysis (rs  0.307, P  0.009, and rs 
0.299, P  0.010, respectively). Moreover, miR-224
expression levels correlated negatively with serum PSA
concentrations (rs  0.284, P  0.015) in patients
with CaP; a negative correlation was also observed in
patients with BPH, but lacked statistical significance
(rs0.275, P 0.056). No correlation was observed
between miR-224 and age.
miR-224 AS A BIOMARKER OF FAVORABLE PROGNOSIS
FOR CaP PATIENTS
WeusedKaplan–Meier progression-free survival curve
analysis (Fig. 3) as a first step of investigating the prog-
nostic properties of miR-224 in prostate cancer. Dis-
ease progression was identified by biochemical relapse.
Patients with CaP categorized as miR-224–positive
(according to the median expression) had a superior
progression-free survival course compared with miR-
224–negative patients (P  0.021). The 5-year cumu-
lative probability of progression-free survival for
Table 2. Binary logistic regression analysis for the occurrence of CaP.
Covariant
Univariate analysis Multivariate analysis
Crude odds
ratio 95% CI Pa
Crude odds
ratio 95% CI Pa
Log10(miR-224) 0.534 0.322–0.884 0.015 0.381 0.168–0.864 0.021
PSA 1.10 1.04–1.15 0.001 1.04 0.969–1.12 0.274
Negative digital rectal exam 1.00 1.00
Positive digital rectal exam 22.0 5.33–90.8 0.001 21.1 4.63–95.9 0.001
a Test for trend.
Fig. 2. Expression of miR-224 in prostate tumors with Gleason Score <6 (n  24), 7 (n  39), and >7 (n  9) (A)
and early (n  34) vs advanced (n  39) pathological stage tumors (B).
*Outliers.
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miR-224–positive patients was 0.797 (0.081) com-
pared with only 0.438 (0.094) for miR-224–negative
patients (Fig. 3).
Bootstrap Cox proportional hazards regression
analysis, at the univariate level, confirmed the favor-
able prognostic properties of miR-224. As the expres-
sion levels of miR-224 increased, patients with CaP
showed a statistically significant (P 0.013) decreased
risk of relapse over time [hazard ratio (HR) 0.314, 95%
CI 0.118–0.712] (Table 3). The above model was also
adjusted for miR-224 expression, Gleason score, path-
ological stage, and preoperative PSA values. In this
multivariate model, only Gleason score retained a
strong independent prognostic value (HR 2.054, 95%
CI 0.975–4.91, P 0.022) (Table 3).
Discussion
miRNAs are well known for their implication in cancer
(6). These molecules could also introduce a new era of
diagnostic, prognostic, and therapeutic modalities for
CaP (3–5), the management of which is affected by the
complexities of PSA testing (1, 2). Toour knowledge, this
is the first study to comprehensively analyze the expres-
sion ofmiR-224 in prostate tumors and provide an initial
investigation of its biomarker potential for CaP.
miR-224 is aberrantly expressed in several human
neoplasms (8–22) and is characterized by contradic-
tory properties, since it can promote (28, 29) or inhibit
(30, 31) cancer cell growth, depending on the malig-
nancy type. miR-224 is upregulated in thyroid tumors
Fig. 3. Kaplan–Meier progression-free survival curves for miR-224–positive and –negative patients.
Table 3. Cox proportional hazards regression analysis of miR-224 expression and clinicopathological variables
for the prediction of progression-free survival, based on 2000 bootstrap samples.
Covariant
Univariate analysis Multivariate analysisa
HR
95% Bootstrap
BCa CIb
Bootstrap
P value HR
95% Bootstrap
BCa CI
Bootstrap
P value
Log10(miR-224) 0.314 0.118–0.712 0.013 0.635 0.137–2.39 0.525
Gleason score (ordinal) 2.41 1.51–6.02 0.001 2.054 0.975–4.91 0.022
Pathological stage (ordinal) 1.47 1.10–2.13 0.005 0.978 0.557–2.17 0.917
Preoperative PSA 1.13 1.02–1.32 0.001 1.076 0.866–1.28 0.143
a Adjusted for log10miR-224 expression, Gleason score, pathological stage and preoperative PSA.
b BCa, bias corrected and accelerated.
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(32); aggressive pancreatic ductal adenocarcinoma
(14); clear cell renal cell carcinoma (15); bladder (20),
hepatocellular (21) and colon cancers (11); a subgroup
of leukemia patients (18); and perineural invasion–
related prostate tumors (19). Conversely, miR-224 is
downregulated, compared to nonmalignant controls,
in ovarian (9 ), lung (8 ), prostate (22), and breast can-
cers (12); malignant giant cell tumor cells (17); and
oral carcinoma (13).
The multifaceted involvement of miR-224 in ma-
lignancy can be explained by the fact that it targets the
expression of several cancer-associated genes. The val-
idated target genes for miR-224 are API5 (apoptosis
inhibitor 5) (21), AP2M1 (adaptor-related protein
complex 2, mu 1 subunit) (33), CDC42 [cell division
cycle 42 (GTP binding protein, 25 kDa)], CXCR4
[chemokine (C-X-C motif) receptor 4] (30), SMAD4
(SMAD family member 4) (34), SMAD5 (SMAD fam-
ily member 5) (17), SLMAP (sarcolemma-associated
protein) (17), H3.3B [H3 histone, family 3B (H3.3B)]
(17), DIO1 (deiodinase, iodothyronine, type I) (16),
DMN1 (33), VHL (von Hippel–Lindau tumor sup-
pressor, E3 ubiquitin protein ligase) (35), HIF1A
[hypoxia-inducible factor 1, alpha subunit (basic
helix-loop-helix transcription factor)] (35), KLK10
(kallikrein-related peptidase 10) (31), and KLK1 (kal-
likrein 1) (36). As far as CaP is concerned, CXCR4 is
overexpressed in prostate malignancies, probably
through posttranscriptional regulation (37 ), and is
associated with the metastatic progression of the dis-
ease (38 ). HIF1A is also highly expressed in cancer-
ous prostate cells and is associated with their malig-
nant phenotypes (39 ). KLK15 (kallikrein-related
peptidase 15), a cancer-related serine protease gene
belonging to the same gene family as PSA (40 ), is
identified among the most probable predicted tar-
gets of miR-224 (31, 36 ). Our group and other re-
search groups have demonstrated the marked up-
regulation of KLK15 in CaP and its association with
progressed disease (40 ).
In the present study, we revealed that miR-224 is
significantly (P  0.001) downregulated in CaP
compared with BPH. Taking a step further, we also
showed that the analysis of miR-224 expression lev-
els can discriminate patients with CaP from patients
with BPH, as indicated by ROC analysis, as well as
both univariate (P  0.015) and multivariate (P 
0.021) binary logistic regression models. Recent
studies conducted on malignant and normal adja-
cent prostate tissue samples have shown that several
other miRNA molecules (e.g., miR-222, -205, -183,
-145), and especially their combinatory use, can pro-
vide important diagnostic information with an en-
hanced AUC (7, 22) compared with that calculated in
this study. Additionally, the AUC of miR-224 seems
inferior when directly compared to established nonin-
vasive prostate cancer biomarkers such as PSA or
prostate cancer antigen 3 (1 ). Additional points for
consideration are that our analysis was performed
after an invasive procedure and that this analysis
cannot substitute for the histological result of the
biopsy. It would be interesting to analyze miR-224
expression at a larger scale, in combination with
other miRNAs, and to include appropriate serum
samples to clearly examine the differential diagnos-
tic capacity of miR-224. Another finding of the pres-
ent study was that miR-224 expression levels were
not correlated with and thus not affected by age in
the CaP or the BPH subgroup. Consequently, the
fact that patients with BPH had a higher mean age
than patients with CaP (Table 1) could not influence
the comparisons regarding miR-224 expression.
As far as miR-224 expression in malignant pros-
tate tumors is concerned, this miRNA was found to be
associated with both less advanced (P 0.018) and less
aggressive (P 0.017) disease. A statistically significant
negative correlation (rs0.284, P 0.015) between
miR224 expression and total serum PSA concentra-
tions was also observed. Taken together, these findings
provide an initial association between increased miR-
224 expression levels and more favorable disease char-
acteristics. High miR-224 expression is also associated
with a more favorable outcome for patients with CaP,
as shown by Kaplan–Meier progression-free survival
curves (P  0.021) and univariate bootstrap Cox re-
gression analysis (P  0.013). Nonetheless, when
miR-224 expression was used in a multivariate
model along with important conventional indicators
of CaP progression (namely Gleason score, patho-
logical stage, and PSA), only Gleason score emerged
as an independent prognostic marker (P 0.022). A
first look at these results reveals the general prognos-
tic superiority of the Gleason score and the rather
limited prediction performance of miR-224 com-
pared to this traditional marker. However, even such
consistent indicators as Gleason score may not al-
ways provide meaningful information for all pa-
tients, given the vast heterogeneity of the disease.
The clinical utility of miR-224 in CaP is yet to be
extensively explored, since this is the first report that
evaluates its capacity as a CaP biomarker. Although
our findings do not provide sufficient justification
for the direct use of miR-224 in routine clinical
decision-making, they are encouraging for further
related research efforts. Future directions could in-
clude the study of miR-224 in patient subgroups
having an unforeseen disease course when conven-
tional prognostic indicators are used.
The above findings may partially contradict with
the study of Prueitt et al. (19) regardingmiR-224 over-
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expression in perineural invasion–related compared to
non–perineural invasion–related prostate tumors.
However, their observation refers to only a subset of
invasive prostate tumors and uses different methods
from the ones described herein. In agreement with our
results, a recent study states thatmiR-224 is downregu-
lated in cancerous compared with normal adjacent
prostate tissue (22). The role of miR-224 as a bio-
marker of favorable prognosis has also been revealed in
medullary thyroid carcinoma, where highmiR-224 ex-
pression is related with earlier disease stages and supe-
rior patient outcome (10).
In conclusion, we demonstrate that miR-224 is
downregulated in CaP compared with BPH, that miR-
244 expression is gradually decreased as malignancy
progresses, and that miR-224 expression is associated
with favorable prognosis. Nonetheless, our study did
not identify miR-224 as an independent prognostic in-
dicator. Additional studies are thus warranted to eval-
uate more broadly the potential of miR-224 as a pros-
tate cancer biomarker.
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